A new near-infrared photothermal therapy precisely destroys P. gingivalis, treats periodontitis, and safeguards the oral microbiome, potentially reducing systemic inflammation and age-related diseases...
Recent research quantifies how systemic inflammation, measured by CRP and immune cells, contributes to mortality risk in older adults, with strong implications for diabetes care. A new large-scale stu...
New economic analysis from the WEF and Nature Aging shows that extending healthy lifespan could yield trillions in annual gains, but only if anti-aging therapies are made universally accessible, not j...
A Nature Aging study found that centenarians harbor Clostridium scindens, which produces indole-3-acetic acid, restoring gut barrier integrity in aged mice and offering new targets for healthy aging t...
Senomorphic drugs aim to tame the harmful effects of senescent cells without killing them, offering a more targeted approach to age-related diseases. A new wave of drugs called senomorphics could chan...
In a Phase 3 trial, the oral drug daraxonrasib roughly doubled median survival in previously treated metastatic pancreatic cancer — 13.2 months versus 6.7 on chemotherapy. Why the first RAS inhibito...
A study in Nature Communications (2025) shows gut-derived imidazole propionate breaks the blood-brain barrier and promotes tau phosphorylation, linking microbiome to Alzheimer’s. A newly discove...
Repair Biotechnologies’ REP-0004 mRNA therapy gains FDA orphan drug designation and demonstrates rapid plaque regression in mouse models, potentially revolutionizing cardiovascular care. An mRNA...
Aged gut microbes release harmful extracellular vesicles that damage tissues, offering new therapeutic targets beyond fecal transplants. A groundbreaking study shows that aged gut bacteria secrete ves...
The 2026 Alzheimer’s clinical trials pipeline shows a strategic shift from amyloid to inflammation and tau targets, with combination therapies and repurposed drugs leading the way. In 2026, the Alzh...